Bladder Cancer test (RuO)
Qlucore Insights Bladder cancer use molecular subtype identification to avoid human uncertainties and improve risk scoring.
The test is based on the molecular defined subtypes from the Lund Taxonomy and also include detection of the FGFR3(1&2) gene fusions as well as NTRK and RET. The test works both on non muscle as well as muscle invasive bladder cancer. The subtypes correlates to tumor stage and can in combination with used risk scoring tools improve the risk score by assisting with the difficult tasks to consistently define tumor stage and grade.
Built on AI-based machine learning, standard lab-workflows and transcriptomics, the test opens new ways for fast, cost efficient and objective sample analysis utilizing both gene expression data and gene fusions.
Contact us to find out more
Current Routine Diagnostics of Bladder Cancer
Risk scoring is used to guide treatment decisions. Tumor stage and grade are input data. It is a difficult task to consistently define tumor stage and grade. The use of AI-based machine learning for subtyping enables a pathway to reduced uncertainties.
Performance (RoU)
The Qlucore Insights Bladder Cancer (RoU) classifier performs gene expression-based subtype classification of the groups listed below.
Sensitivity measured using nested cross validation on the training data set of 834 samples range from 0,88 for the challenging subtype Small cell Neuroendocrine-like to 0,99 and specificity starts at 0,98 for the Uro group and is 0,99 for the other subtypes.
The test lists FGFR3(1&2) gene fusions as well as NTRK, RET and potentially novel ones.
The test detects the following subtypes:
- Basal squamous-like (Ba/Sq)
- Genomically Unstable (GU)
- Mesenchymal-like (Mes-like)
- Small cell Neuroendocrine-like (Sc/NE)
- Urothelial-like (Uro)
Sample type: Fresh frozen from TURBT
Reach out for more detailed information.